Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Pantoprazole GPO 40 mg vs CONTROLOC 40 mg under fed conditions in healthy adults
TCTR20191114002Not yet recruiting
- Sponsor
- Government Pharmaceutical Organization
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pantoprazole in gastroesophageal reflux disease (GERD), Peptic ulcer disease (PUD) and erosive esophagitis (EE) (2 arms), sponsored by Government Pharmaceutical Organization. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
pantoprazole
03
Conditions
gastroesophageal reflux disease (GERD)Peptic ulcer disease (PUD)erosive esophagitis (EE)
Beyond the preview
Go deeper on TCTR20191114002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20191114002.